FDA labels AbbVie hep C drug Breakthrough

Share this article:

Abbvie and partner Enanta Pharmaceuticals have tucked a Breakthrough Therapy label under their belts. The FDA granted the expedited review status Friday to the experimental hepatitis C treatment that includes protease inhibitor ABT-450 and ombitasvir and dasabuvir, with or without the interferon ribavirin.

The all-oral's progress means the FDA will review the drug within six months, and that AbbVie deposited an additional milestone payment into Enanta's accounts.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.